PDX model details
| PDX ID |
435.7A |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
4 |
| Average PDX Generation Time (days +/- SEM) |
57 ± 8 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
435.7A |
| AR |
N |
| PSA |
N |
| PSMA |
N |
| NE |
Y |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 435.7A |
CDH1 |
-1.150 |
0.901 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
TP53 |
-28.561 |
5.050e-09 |
Homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
APC |
-1.022 |
0.985 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
CHD1 |
-1.022 |
0.985 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
ZNRF3 |
-0.950 |
1.035 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
ZNRF3 |
-1.202 |
0.869 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
FANCA |
-1.138 |
0.909 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
ZFHX3 |
-0.892 |
1.078 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
ZFHX3 |
-1.150 |
0.901 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
PIK3CB |
1.128 |
4.372 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
MGA |
-1.054 |
0.964 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
RB1 |
-1.330 |
0.796 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
BRCA2 |
-0.986 |
1.010 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
CDKN1B |
-0.999 |
1.001 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
PAX6 |
-0.935 |
1.046 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
SUFU |
-0.985 |
1.010 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
CUL3 |
-0.936 |
1.046 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 435.7A |
ERBB4 |
-0.936 |
1.046 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
435.7A |
| Sample Site |
Front-parietal lobe |
| Sample source |
Autopsy |
| Pathology Tumour Diagnosis |
None |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, carboplatin plus etoposide |
| |
|
Patient Information
| Patient Number |
435 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
16.2 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download Plot
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Total Read Depth
|
Alternate Frequency
|
Consequence
|
Exon
|
GnomAD AF
|
CADD PHRED score
|
ClinVar significance
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 435.7A |
BRCA2 |
194 |
0.98 |
Frameshift variant |
'11/28 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.7A |
SUPV3L1 |
567 |
0.63 |
Missense variant |
'13/15 |
. |
31 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.7A |
ATAD2B |
295 |
0.53 |
Missense variant |
'1/28 |
. |
25.1 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.7A |
TSHR |
544 |
0.5 |
Missense variant |
'11/11 |
. |
27.2 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.7A |
IRF4 |
402 |
0.46 |
Missense variant |
'3/9 |
3.66E-05 |
21.5 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.7A |
NOTCH2 |
493 |
0.43 |
Frameshift variant |
'34/34 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.7A |
PRKDC |
291 |
0.42 |
Missense variant |
'1/87 |
. |
24.9 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 435.7A |
KMT2C |
708 |
0.27 |
Stop gained |
'16/59 |
. |
35 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Drug dosing Table